THU0230 Anti-TNF Alpha Drugs Retention Rate at Ankylosing Spondylitis and Axial Spondyloarthritis: HUR-BIO Real Life Results

BackgroundAnti-TNF alpha (TNFi) drug survival is one of the relevant outcome measure in rheumatological diseases.ObjectivesObjective of this study was to compare TNFi drug survival in ankylosing spondylitis (AS) and axial spondyloarthritis (AxSpA).MethodsHUR-BIO (Hacettepe University Rheumatology Bi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.279-280
Hauptverfasser: Kalyoncu, U., Babaoglu, H., Erden, A., Kilic, L., Torgutalp, M., Karadag, O., Kilickap, S., Akdogan, A., Bilgen, S.A., Ertenli, I., Kiraz, S.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 280
container_issue Suppl 2
container_start_page 279
container_title Annals of the rheumatic diseases
container_volume 74
creator Kalyoncu, U.
Babaoglu, H.
Erden, A.
Kilic, L.
Torgutalp, M.
Karadag, O.
Kilickap, S.
Akdogan, A.
Bilgen, S.A.
Ertenli, I.
Kiraz, S.
description BackgroundAnti-TNF alpha (TNFi) drug survival is one of the relevant outcome measure in rheumatological diseases.ObjectivesObjective of this study was to compare TNFi drug survival in ankylosing spondylitis (AS) and axial spondyloarthritis (AxSpA).MethodsHUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single center biological registry since 2005. HUR-BIO biological dataset included demographic data, education level, co-morbidities, smoking, BMI, HLA-B27, switch ratio, baseline and follow-up disease activity parameters (such as BASDAI, BASFI, CRP, ESR, global VAS). Patients with lost of follow-up searched regarding to last TNFi prescription date with either local computer system or national social security institution database. Inition and last date of TNFi were noted from those systems. First TNFi drug switch date (either advers event or inefficacy) was accepted as main variable for drug survival. Kaplan-Meier plots and log rank tests were used to assess drug survival. HUR-BIO is not sponsored by any pharmaceutical company. Missing data ratio of baseline disease activity measures were 38.5% at BASDAI, 22.1% at ESR, 23.9% at CRP and 60.6% at BASFI.ResultsThere were 874 patients (747 AS and 127 AxSpA). Mean age was 40.7±11.4 years old. Overall, 533 (61%) of patients were male, mean disease duration was 8.3±7.1 years and mean symptom duration was 12.8±8.9 years. Initial biological drugs were etanercept 346 (39.6%), infliximab 270 (30.9%) and adalimumab 258 (29.5%). Overall, initial biological drugs were continued at 497 (56.9%) patients. Of 245 (29.7%) patients had at least one biological switch. First biological drug survival was more frequent at male sex (61.4% vs 49.8%, p=0.001) and patients with highest ESR level (31.6 (23.7) vs 27.8 (22.3) mm/hour, p=0.041). In logistic regression analysis, male sex had tendency of better TNFi drugs survival [OR 1.65 (95%CI 0.96-2.83), p=0.070]. Patients with use usage of etanercept had tendency of more frequent drugs survival than monoclonal antibodies (log-rank p=0.057) (Table and Figure 1). Retention rate was similar at both AS and AxSpA patients.Table 1.Retention rate of different anti-TNF drugs6 months1 year2 years3 years4 years5 yearsAdalimumab (%)888174675955Infliximab (%)938476706458Etanercept (%)888578767168ConclusionsIn this single center observational registry, etanercept had tendency of better drug retention rate than monoclonal antibodies. Overall, anti-TNF drugs retention rate was well bo
doi_str_mv 10.1136/annrheumdis-2015-eular.4196
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901808039</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322507223</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1279-fde8788efbaa302659bee626a897827d70f95a0a15c236f84f8eee60f1617ca63</originalsourceid><addsrcrecordid>eNqVkMtOwzAQRS0EEqXwD5a6Thnn4TiwCo_SShWVSru2nMZuU1In2IlEN4gNP8qX4FCQ2LKamTv3zkgHoQGBISEBvRRam41sd3lhPR9I5Mm2FGYYkoQeoR4JKXMyhWPUA4DACxMan6Iza7duBEZYD70txkvwA_h8_0h1U3iLxxFOy3oj8J1p1xbPZSOdXmk8F43EosGpft6XlS30Gj_Vlc73ZdEUFgud4_S1EOWvWgnTbEy3u8Lj5dy7mczcNbefFkq6zrZlY8_RiRKllRc_tY-Wo_vF7dibzh4mt-nUy4gfJ57KJYsZkyoTIgCfRkkmJfWpYEnM_DiPQSWRAEGilR9QxULFpDOAIpTEK0GDPhoc7tamemmlbfi2ao12LzlJgDBgECTOdX1wrUxlrZGK16bYCbPnBHgHnP8Bzjvg_Bs474C7ND2ks932X8Evta2NGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901808039</pqid></control><display><type>article</type><title>THU0230 Anti-TNF Alpha Drugs Retention Rate at Ankylosing Spondylitis and Axial Spondyloarthritis: HUR-BIO Real Life Results</title><source>BMJ Journals - NESLi2</source><creator>Kalyoncu, U. ; Babaoglu, H. ; Erden, A. ; Kilic, L. ; Torgutalp, M. ; Karadag, O. ; Kilickap, S. ; Akdogan, A. ; Bilgen, S.A. ; Ertenli, I. ; Kiraz, S.</creator><creatorcontrib>Kalyoncu, U. ; Babaoglu, H. ; Erden, A. ; Kilic, L. ; Torgutalp, M. ; Karadag, O. ; Kilickap, S. ; Akdogan, A. ; Bilgen, S.A. ; Ertenli, I. ; Kiraz, S.</creatorcontrib><description>BackgroundAnti-TNF alpha (TNFi) drug survival is one of the relevant outcome measure in rheumatological diseases.ObjectivesObjective of this study was to compare TNFi drug survival in ankylosing spondylitis (AS) and axial spondyloarthritis (AxSpA).MethodsHUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single center biological registry since 2005. HUR-BIO biological dataset included demographic data, education level, co-morbidities, smoking, BMI, HLA-B27, switch ratio, baseline and follow-up disease activity parameters (such as BASDAI, BASFI, CRP, ESR, global VAS). Patients with lost of follow-up searched regarding to last TNFi prescription date with either local computer system or national social security institution database. Inition and last date of TNFi were noted from those systems. First TNFi drug switch date (either advers event or inefficacy) was accepted as main variable for drug survival. Kaplan-Meier plots and log rank tests were used to assess drug survival. HUR-BIO is not sponsored by any pharmaceutical company. Missing data ratio of baseline disease activity measures were 38.5% at BASDAI, 22.1% at ESR, 23.9% at CRP and 60.6% at BASFI.ResultsThere were 874 patients (747 AS and 127 AxSpA). Mean age was 40.7±11.4 years old. Overall, 533 (61%) of patients were male, mean disease duration was 8.3±7.1 years and mean symptom duration was 12.8±8.9 years. Initial biological drugs were etanercept 346 (39.6%), infliximab 270 (30.9%) and adalimumab 258 (29.5%). Overall, initial biological drugs were continued at 497 (56.9%) patients. Of 245 (29.7%) patients had at least one biological switch. First biological drug survival was more frequent at male sex (61.4% vs 49.8%, p=0.001) and patients with highest ESR level (31.6 (23.7) vs 27.8 (22.3) mm/hour, p=0.041). In logistic regression analysis, male sex had tendency of better TNFi drugs survival [OR 1.65 (95%CI 0.96-2.83), p=0.070]. Patients with use usage of etanercept had tendency of more frequent drugs survival than monoclonal antibodies (log-rank p=0.057) (Table and Figure 1). Retention rate was similar at both AS and AxSpA patients.Table 1.Retention rate of different anti-TNF drugs6 months1 year2 years3 years4 years5 yearsAdalimumab (%)888174675955Infliximab (%)938476706458Etanercept (%)888578767168ConclusionsIn this single center observational registry, etanercept had tendency of better drug retention rate than monoclonal antibodies. Overall, anti-TNF drugs retention rate was well both AS and AxSpA than rheumatoid arthritis. On the other hand, certain confounder factors such as baseline disease activity, functional status were not known in whole patients, thus our results should evaluate in this limitationDisclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.4196</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.279-280</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/279.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/279.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Kalyoncu, U.</creatorcontrib><creatorcontrib>Babaoglu, H.</creatorcontrib><creatorcontrib>Erden, A.</creatorcontrib><creatorcontrib>Kilic, L.</creatorcontrib><creatorcontrib>Torgutalp, M.</creatorcontrib><creatorcontrib>Karadag, O.</creatorcontrib><creatorcontrib>Kilickap, S.</creatorcontrib><creatorcontrib>Akdogan, A.</creatorcontrib><creatorcontrib>Bilgen, S.A.</creatorcontrib><creatorcontrib>Ertenli, I.</creatorcontrib><creatorcontrib>Kiraz, S.</creatorcontrib><title>THU0230 Anti-TNF Alpha Drugs Retention Rate at Ankylosing Spondylitis and Axial Spondyloarthritis: HUR-BIO Real Life Results</title><title>Annals of the rheumatic diseases</title><description>BackgroundAnti-TNF alpha (TNFi) drug survival is one of the relevant outcome measure in rheumatological diseases.ObjectivesObjective of this study was to compare TNFi drug survival in ankylosing spondylitis (AS) and axial spondyloarthritis (AxSpA).MethodsHUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single center biological registry since 2005. HUR-BIO biological dataset included demographic data, education level, co-morbidities, smoking, BMI, HLA-B27, switch ratio, baseline and follow-up disease activity parameters (such as BASDAI, BASFI, CRP, ESR, global VAS). Patients with lost of follow-up searched regarding to last TNFi prescription date with either local computer system or national social security institution database. Inition and last date of TNFi were noted from those systems. First TNFi drug switch date (either advers event or inefficacy) was accepted as main variable for drug survival. Kaplan-Meier plots and log rank tests were used to assess drug survival. HUR-BIO is not sponsored by any pharmaceutical company. Missing data ratio of baseline disease activity measures were 38.5% at BASDAI, 22.1% at ESR, 23.9% at CRP and 60.6% at BASFI.ResultsThere were 874 patients (747 AS and 127 AxSpA). Mean age was 40.7±11.4 years old. Overall, 533 (61%) of patients were male, mean disease duration was 8.3±7.1 years and mean symptom duration was 12.8±8.9 years. Initial biological drugs were etanercept 346 (39.6%), infliximab 270 (30.9%) and adalimumab 258 (29.5%). Overall, initial biological drugs were continued at 497 (56.9%) patients. Of 245 (29.7%) patients had at least one biological switch. First biological drug survival was more frequent at male sex (61.4% vs 49.8%, p=0.001) and patients with highest ESR level (31.6 (23.7) vs 27.8 (22.3) mm/hour, p=0.041). In logistic regression analysis, male sex had tendency of better TNFi drugs survival [OR 1.65 (95%CI 0.96-2.83), p=0.070]. Patients with use usage of etanercept had tendency of more frequent drugs survival than monoclonal antibodies (log-rank p=0.057) (Table and Figure 1). Retention rate was similar at both AS and AxSpA patients.Table 1.Retention rate of different anti-TNF drugs6 months1 year2 years3 years4 years5 yearsAdalimumab (%)888174675955Infliximab (%)938476706458Etanercept (%)888578767168ConclusionsIn this single center observational registry, etanercept had tendency of better drug retention rate than monoclonal antibodies. Overall, anti-TNF drugs retention rate was well both AS and AxSpA than rheumatoid arthritis. On the other hand, certain confounder factors such as baseline disease activity, functional status were not known in whole patients, thus our results should evaluate in this limitationDisclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkMtOwzAQRS0EEqXwD5a6Thnn4TiwCo_SShWVSru2nMZuU1In2IlEN4gNP8qX4FCQ2LKamTv3zkgHoQGBISEBvRRam41sd3lhPR9I5Mm2FGYYkoQeoR4JKXMyhWPUA4DACxMan6Iza7duBEZYD70txkvwA_h8_0h1U3iLxxFOy3oj8J1p1xbPZSOdXmk8F43EosGpft6XlS30Gj_Vlc73ZdEUFgud4_S1EOWvWgnTbEy3u8Lj5dy7mczcNbefFkq6zrZlY8_RiRKllRc_tY-Wo_vF7dibzh4mt-nUy4gfJ57KJYsZkyoTIgCfRkkmJfWpYEnM_DiPQSWRAEGilR9QxULFpDOAIpTEK0GDPhoc7tamemmlbfi2ao12LzlJgDBgECTOdX1wrUxlrZGK16bYCbPnBHgHnP8Bzjvg_Bs474C7ND2ks932X8Evta2NGg</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Kalyoncu, U.</creator><creator>Babaoglu, H.</creator><creator>Erden, A.</creator><creator>Kilic, L.</creator><creator>Torgutalp, M.</creator><creator>Karadag, O.</creator><creator>Kilickap, S.</creator><creator>Akdogan, A.</creator><creator>Bilgen, S.A.</creator><creator>Ertenli, I.</creator><creator>Kiraz, S.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>THU0230 Anti-TNF Alpha Drugs Retention Rate at Ankylosing Spondylitis and Axial Spondyloarthritis: HUR-BIO Real Life Results</title><author>Kalyoncu, U. ; Babaoglu, H. ; Erden, A. ; Kilic, L. ; Torgutalp, M. ; Karadag, O. ; Kilickap, S. ; Akdogan, A. ; Bilgen, S.A. ; Ertenli, I. ; Kiraz, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1279-fde8788efbaa302659bee626a897827d70f95a0a15c236f84f8eee60f1617ca63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kalyoncu, U.</creatorcontrib><creatorcontrib>Babaoglu, H.</creatorcontrib><creatorcontrib>Erden, A.</creatorcontrib><creatorcontrib>Kilic, L.</creatorcontrib><creatorcontrib>Torgutalp, M.</creatorcontrib><creatorcontrib>Karadag, O.</creatorcontrib><creatorcontrib>Kilickap, S.</creatorcontrib><creatorcontrib>Akdogan, A.</creatorcontrib><creatorcontrib>Bilgen, S.A.</creatorcontrib><creatorcontrib>Ertenli, I.</creatorcontrib><creatorcontrib>Kiraz, S.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kalyoncu, U.</au><au>Babaoglu, H.</au><au>Erden, A.</au><au>Kilic, L.</au><au>Torgutalp, M.</au><au>Karadag, O.</au><au>Kilickap, S.</au><au>Akdogan, A.</au><au>Bilgen, S.A.</au><au>Ertenli, I.</au><au>Kiraz, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0230 Anti-TNF Alpha Drugs Retention Rate at Ankylosing Spondylitis and Axial Spondyloarthritis: HUR-BIO Real Life Results</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>279</spage><epage>280</epage><pages>279-280</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundAnti-TNF alpha (TNFi) drug survival is one of the relevant outcome measure in rheumatological diseases.ObjectivesObjective of this study was to compare TNFi drug survival in ankylosing spondylitis (AS) and axial spondyloarthritis (AxSpA).MethodsHUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single center biological registry since 2005. HUR-BIO biological dataset included demographic data, education level, co-morbidities, smoking, BMI, HLA-B27, switch ratio, baseline and follow-up disease activity parameters (such as BASDAI, BASFI, CRP, ESR, global VAS). Patients with lost of follow-up searched regarding to last TNFi prescription date with either local computer system or national social security institution database. Inition and last date of TNFi were noted from those systems. First TNFi drug switch date (either advers event or inefficacy) was accepted as main variable for drug survival. Kaplan-Meier plots and log rank tests were used to assess drug survival. HUR-BIO is not sponsored by any pharmaceutical company. Missing data ratio of baseline disease activity measures were 38.5% at BASDAI, 22.1% at ESR, 23.9% at CRP and 60.6% at BASFI.ResultsThere were 874 patients (747 AS and 127 AxSpA). Mean age was 40.7±11.4 years old. Overall, 533 (61%) of patients were male, mean disease duration was 8.3±7.1 years and mean symptom duration was 12.8±8.9 years. Initial biological drugs were etanercept 346 (39.6%), infliximab 270 (30.9%) and adalimumab 258 (29.5%). Overall, initial biological drugs were continued at 497 (56.9%) patients. Of 245 (29.7%) patients had at least one biological switch. First biological drug survival was more frequent at male sex (61.4% vs 49.8%, p=0.001) and patients with highest ESR level (31.6 (23.7) vs 27.8 (22.3) mm/hour, p=0.041). In logistic regression analysis, male sex had tendency of better TNFi drugs survival [OR 1.65 (95%CI 0.96-2.83), p=0.070]. Patients with use usage of etanercept had tendency of more frequent drugs survival than monoclonal antibodies (log-rank p=0.057) (Table and Figure 1). Retention rate was similar at both AS and AxSpA patients.Table 1.Retention rate of different anti-TNF drugs6 months1 year2 years3 years4 years5 yearsAdalimumab (%)888174675955Infliximab (%)938476706458Etanercept (%)888578767168ConclusionsIn this single center observational registry, etanercept had tendency of better drug retention rate than monoclonal antibodies. Overall, anti-TNF drugs retention rate was well both AS and AxSpA than rheumatoid arthritis. On the other hand, certain confounder factors such as baseline disease activity, functional status were not known in whole patients, thus our results should evaluate in this limitationDisclosure of InterestNone declared</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2015-eular.4196</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.279-280
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901808039
source BMJ Journals - NESLi2
title THU0230 Anti-TNF Alpha Drugs Retention Rate at Ankylosing Spondylitis and Axial Spondyloarthritis: HUR-BIO Real Life Results
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T09%3A16%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0230%E2%80%85Anti-TNF%20Alpha%20Drugs%20Retention%20Rate%20at%20Ankylosing%20Spondylitis%20and%20Axial%20Spondyloarthritis:%20HUR-BIO%20Real%20Life%20Results&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Kalyoncu,%20U.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=279&rft.epage=280&rft.pages=279-280&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.4196&rft_dat=%3Cproquest_cross%3E4322507223%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901808039&rft_id=info:pmid/&rfr_iscdi=true